X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-i-clinical-trial-findings-of-a-cabotegravir-long-acting-injectable-investigational-formulation/
https://www.gsk.com/en-gb/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-approval-from-nmpa-for-vocabria-in-combination-with-rekambys/
https://www.reuters.com/business/healthcare-pharmaceuticals/european-commission-authorises-gsks-hiv-prevention-drug-2023-09-19/
https://www.fiercepharma.com/pharma/msf-trying-secure-gsks-viivs-long-acting-hiv-prep-calls-out-nda-clauses-purchasing-contract
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-european-medicines-agency/
https://www.fiercepharma.com/pharma/gsks-viiv-explores-novel-pathway-bring-long-acting-hiv-drug-cabenuva-tough-populations
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-licenses-companies-make-cheap-copies-hiv-prevention-drug-2023-03-30/
https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-viiv-says-study-shows-its-long-acting-hiv-shot-effective-gileads-daily-pill-2023-02-22/
https://www.fiercepharma.com/pharma/gileads-lenacapivir-approved-first-class-long-acting-hiv-injectable
https://www.fiercepharma.com/marketing/gsks-hiv-franchise-could-reach-ps7b-2026-analyst-says-real-world-data-start-backing-long
https://www.fiercepharma.com/pharma/gsk-still-early-us-launch-licenses-long-acting-hiv-prep-drug-apretude-patent-pool-poorer
https://www.jnj.com/u-s-fda-approves-cabenuva-cabotegravir-and-rilpivirine-for-adolescents-expanding-the-indication-of-the-first-and-only-complete-long-acting-injectable-hiv-regimen
https://endpts.com/with-competitors-circling-viiv-wins-another-label-update-for-long-acting-hiv-injectable-cabenuva/
https://www.fiercepharma.com/pharma/glaxosmithkline-first-long-acting-hiv-prep-injectable-apretude-fda-approval-threaten-gilead
http://www.pharmafile.com/news/600703/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-injectable-form-gsk-hiv-prevention-drug-2021-12-20/
https://www.expresspharma.in/fda-approves-first-injectable-treatment-for-hiv-pre-exposure-prevention/
https://www.healio.com/news/infectious-disease/20211220/fda-approves-first-longacting-injectable-for-hiv-prevention
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-interim-data-showing-vocabria-cabotegravir-and-rekambys-rilpivirine-can-be-implemented-successfully-in-a-variety-of-european-healthcare-settings/
https://www.fiercepharma.com/pharma/glaxosmithkline-don-t-wait-for-shingrix-rebound-year-but-2022-could-see-record-sales
https://pharmafield.co.uk/pharma_news/positive-smc-decision-for-first-long-acting-injectable-hiv-treatment/
https://www.fiercebiotech.com/biotech/shionogi-licences-third-gen-hiv-asset-ultra-long-dosing-prospect-from-its-partly-owned
https://www.fiercepharma.com/pharma/priority-review-status-gsk-moves-step-closer-to-approval-long-acting-hiv-prep-drug
https://viivhealthcare.com/en-gb/media/press-releases/2021/July/viiv-healthcare-study-shows-new-long-acting-hiv-regimen-cabenuva/
https://www.fiercepharma.com/marketing/gsk-viiv-s-debuts-cabenuva-marketing-centering-real-patients-and-educating-hcps
https://www.pharmaceutical-technology.com/news/viiv-rolling-submission-cabotegravir/
https://www.europeanpharmaceuticalreview.com/news/140642/fda-approves-first-extended-release-injectable-complete-regimen-for-hiv-cabenuva/
https://www.prnewswire.com/news-releases/janssen-announces-us-fda-approval-of-cabenuva-rilpivirine-and-cabotegravir-the-first-long-acting-regimen-for-the-treatment-of-hiv-301213000.html
https://endpts.com/gsk-and-viiv-score-breakthrough-therapy-designation-in-hiv-prevention-as-truvada-showdown-draws-nearer/
http://www.pharmatimes.com/news/viivs_cabotegravir_scores_breakthrough_designation_for_hiv_prevention_1357172
https://www.reuters.com/article/us-gsk-viiv-fda-resubmission/gsk-says-it-is-within-weeks-of-resubmitting-hiv-injection-cabenuva-idUSKBN24326Q
https://www.lgbtqnation.com/2020/05/new-long-acting-prep-injection-found-effectively-prevent-hiv-transmission/
https://www.globenewswire.com/news-release/2020/05/18/2034827/0/en/Long-Acting-Injectable-Cabotegravir-Is-Highly-Effective-for-the-Prevention-of-HIV-Infection-in-Cisgender-Men-and-Transgender-Women-Who-Have-Sex-With-Men.html
http://www.pharmatimes.com/news/viiv_sees_first_global_approval_of_cabenuva_in_canada_1329795
https://www.fiercepharma.com/pharma/take-fda-gsk-s-viiv-scores-canadian-nod-for-once-monthly-hiv-regimen-cabenuva
https://www.prnewswire.com/news-releases/newly-licensed-independent-pharmacy-owned-indy-health-insurance-to-launch-medicare-d-plan-this-fall-301019362.html
https://www.prnewswire.com/news-releases/complete-response-letter-issued-from-us-fda-for-investigational-long-acting-hiv-regimen-300978678.html
https://endpts.com/top-gsk-viiv-scientist-who-co-invented-an-hiv-blockbuster-books-a-trip-to-biotech/
https://www.biospectrumasia.com/news/39/14301/janssen-reports-positive-ph3-results-of-long-acting-injectable-hiv-treatment-regimen-.html
https://endpts.com/eight-weeks-between-each-hiv-treatment-gsk-notches-phiii-win-as-it-chases-ok-for-long-acting-regimen/
https://www.clinicaltrialsarena.com/news/viiv-long-acting-regimen-hiv/
Market Place
Share 
